Fitlife Brands, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Irwin at $14.1 million, 53% of the total. By sales mix, the largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Irwin at $14.1 million, 53% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
36
|
27
|
25
|
-40
|
23
|
16
|
16
|
15
|
16
|
| Operating segments | |||||||||
| Irwin |
—
|
14
share 53.2%
|
13
share 50.7%
|
13
share -31.9%
|
7
share 29.0%
|
—
|
—
|
—
|
—
|
| Legacy Fit Life |
—
|
12
+70.0%
share 46.8%
|
12
share 49.3%
|
22
+228.2%
share -54.5%
|
13
-4.9%
share 54.7%
|
7
share 45.3%
|
—
|
-17
share -112.2%
|
14
share 84.6%
|
| Sales mix | |||||||||
| Irwin |
—
|
14
share 53.2%
|
13
share 50.7%
|
13
share -31.9%
|
7
share 29.0%
|
—
|
—
|
—
|
—
|
| Legacy Fit Life |
—
|
12
+70.0%
share 46.8%
|
12
share 49.3%
|
22
+228.2%
share -54.5%
|
13
-4.9%
share 54.7%
|
7
share 45.3%
|
—
|
-17
share -112.2%
|
14
share 84.6%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- FTLF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Omaha, NE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1374328
- Former names
- BOND LABORATORIES, INC. (until Oct 1, 2013)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.